Cue Biopharma, Inc.

NASDAQ:CUE

Biotechnology

Healthcare
$14.10 +1.42%

+$0.38 today

Market cap
$102.43M
Beta
2.53
P/E (TTM)
-6.7
EPS (TTM)
-$4.06
52W Low $4.98High $41.42

Volume 0.21M

Average 0.74M

Income Statement

Follow revenue through to earnings.

Revenue

$27.47M

FY 2025 · Annual

+195.7% YoY

Operating Income

-$26.52M

FY 2025 · Annual

Net Income

-$26.60M

FY 2025 · Annual

Income Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Revenue14.94M1.25M5.49M9.29M27.47M
Cost of Revenue(1.78M)038.1M00
Gross Profit16.72M1.25M(32.61M)9.29M27.47M
Gross Margin111.9%100.0%-593.9%100.0%100.0%
Research & Development41.35M38.58M40.8M36.3M37.74M
Selling, General & Admin17.31M16.17M16.68M14.59M16.24M
Operating Expenses60.43M54.47M19.54M50.79M53.99M
Depreciation & Amortization(1.78M)1.81M3.44M2.35M3.48M
EBITDA(45.44M)(50.49M)(46.05M)(37.53M)(22.27M)
EBITDA Margin-304.1%-4055.5%-838.8%-404.1%-81.1%
Operating Income(43.71M)(53.23M)(52.15M)(41.5M)(26.52M)
Operating Margin-292.6%-4275.1%-949.9%-446.9%-96.6%
Interest Income45.9K928.24K2.66M1.62M807K
Interest Expense0713.82K1.25M796K357K
Other Income / Expenses45.9K215K1.42M826K419K
Income Before Tax(43.67M)(53.01M)(50.73M)(40.67M)(26.1M)
Pre-Tax Margin-292.3%-4257.8%-924.1%-438.0%-95.0%
Income Tax Expense495K000500K
Net Income(44.16M)(53.01M)(50.73M)(40.67M)(26.6M)
Net Margin-295.6%-4257.8%-924.1%-438.0%-96.9%
EPS (Basic)(42.30)(44.70)(33.30)(21.60)(8.40)
EPS (Diluted)(42.30)(44.70)(33.30)(21.60)(8.40)
Weighted Avg Shares1.04M1.19M1.53M1.88M3.16M
Weighted Avg Shares (Diluted)1.04M1.19M1.53M1.88M3.16M

CUE Earnings Waterfall · TTM

NASDAQ:CUE · Revenue to Net Income

Key Ratios

EPS$-5.53
Gross Margin99.1%
Net Margin-179.4%
P/E Ratio-0.2
P/S Ratio15.8

Analysis

$32.7M of revenue converted into -$19.5M of net income for the selected period. Gross margin is 99.1% and net margin is -179.4%, showing how much revenue survives after costs and taxes. EPS is $-5.53, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 10, 2026
4Statement of changes in beneficial ownershipOct 14, 2026
4Statement of changes in beneficial ownershipOct 14, 2026
4Statement of changes in beneficial ownershipOct 14, 2026
SC 13G/ASC 13G/A filingOct 8, 2026

How much revenue does CUE generate?

Cue Biopharma, Inc. (CUE) reported $27.47M of revenue in fiscal 2025.

Is CUE profitable?

Cue Biopharma, Inc. (CUE) reported -$26.60M of net income, with a net margin of -96.9%.